Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
The Lancet Oncology Feb 15, 2018
Atkins MB, et al. - Axitinib, a more selective VEGF inhibitor than others previously tested, was hypothesized to combine safely with pembrolizumab (anti-PD-1) and yield anti-tumour activity in patients with treatment-naive advanced renal cell carcinoma. Axitinib + pembrolizumab was tolerable and showed promising antitumour activity in patients with treatment-naive advanced renal cell carcinoma.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
